Johnson & Johnson
JNJ 170.59 (-0.09%) 0.15
410.84(B)
Health Care
Pharmaceuticals
My Holdings:
(?% ownership)
Shares:
Cost basis:
Market cap:$410.84(B)
EV:$451.83(B)
Total Equity:$78.47(B)
Div. yield:2.94%
Earnings date:Oct-14-2025
P/E:18.11
P/E (fwd):15.72
P/FCF:22.13
P/S:4.53
P/B:5.23
EPS:$9.4
EPS (fwd):$10.8
FCF/share:$7.7
Dividend/share:$5.0
Book value/share:$32.6
ROIC:18.7%
ROA:12.1%
ROE:30.2%
Gross margin:68.4%
Net margin:25.0%
Valuation Summary TTM Financials Growth Estimates Historical Data KPIs Similar Companies Ownership Tools
JNJ Valuation & Price Targets
Current Price
PE Valuation
PEvaluation is not available for JNJ.
Analyst targets
No analyst estimates for JNJ.
DCF
Adjust your assumptions to reach a valid valuation.
DCF (exit mult.)
Adjust your assumptions to reach a valid valuation.
Future P/E
Adjust your assumptions to reach a valid valuation.
Peter Lynch FV
Adjust your assumptions to reach a valid valuation.
Graham No.
Adjust your assumptions to reach a valid valuation.
DDM
Adjust your assumptions to reach a valid valuation.
PEvaluation
8% overvalued
Low
$118
Mid
$157
High
$196
Current price
$171
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: Wide
Estimated EPS
| Low | Avg | High | # | |
| FY+1 | 10.6 | 10.8 | 11.0 | 22 |
| FY+2 | 10.8 | 11.4 | 12.1 | 25 |
| FY+3 | 10.9 | 12.1 | 13.0 | 18 |
| FY+4 | 11.3 | 12.6 | 13.6 | 6 |
| FY+5 | 12.3 | 13.5 | 14.9 | 6 |
Analyst Price Targets
3% undervalued
Low
$155
Mid
$175
High
$190
Current price
$171
Estimated EPS
| Low | Avg | High | # | |
| FY+1 | 10.6 | 10.8 | 11.0 | 22 |
| FY+2 | 10.8 | 11.4 | 12.1 | 25 |
| FY+3 | 10.9 | 12.1 | 13.0 | 18 |
| FY+4 | 11.3 | 12.6 | 13.6 | 6 |
| FY+5 | 12.3 | 13.5 | 14.9 | 6 |
Discounted Cash Flow
| Forecast years | |
| Terminal Growth Rate | |
| Discount Rate |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
| Forecast years | |
| Exit FCF Multiple | |
| Discount Rate |
Free cash flow estimates:
Future P/E Valuation
| Projection Years | |
| Base Revenue | |
| Revenue Growth Rate | |
| Final Net Margin | |
| Final P/E Ratio | |
| Discount Rate |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate (*) |
(*) Growth rate is capped between 0 and 25
Graham Formula
| Earnings Per Share | |
| Expected Growth Rate | |
| Government Bond Rate |
(*) Growth rate is capped to 25
Dividend Discount Model
| Annual Dividend | |
| First Stage Length (Years) | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate |
(*) First stage rowth rate is capped to 20%
Summary
TTM Financials
Income (TTM)
Revenue$90.63(B)
Gross profit$62.00(B)
EBITDA$30.25(B)
Net income$22.66(B)
Gross margin68.4%
Operating margin24.5%
Net margin25.0%
Shares outstanding:2.41(B)
Balance sheet
Total assets$193.39(B)
Current assets$54.50(B)
Total liabilities$114.92(B)
Current liabilities$54.18(B)
Cash & Short-term inv.$18.88(B)
Long-term debt$39.23(B)
Total intangibles$97.95(B)
PP&E$21.95(B)
Cash flow (TTM)
FCF$18.55(B)
CapEx$-4.48(B)
Dividends paid$-12.09(B)
Stock issued$1.10(B)
Stock repurchased$-2.95(B)
Stock-based comp.$1.23(B)
Debt issued$19.79(B)
Debt repaid$-12.01(B)
Per share data (TTM)
Growth Estimates
Revenue
CAGR: 4.3%FY+1$93.41(B)
FY+2(+4.2%)$97.30(B)
FY+3(+4.3%)$101.46(B)
FY+4(+4.3%)$105.81(B)
FY+5(+4.7%)$110.75(B)
Net Income
CAGR: 4.9%FY+1$26.24(B)
FY+2(+4.3%)$27.37(B)
FY+3(+6.5%)$29.15(B)
FY+4(+1.9%)$29.71(B)
FY+5(+7.0%)$31.78(B)
EPS
CAGR: 5.7%FY+1$10.85
FY+2(+4.7%)$11.36
FY+3(+6.6%)$12.11
FY+4(+3.7%)$12.56
FY+5(+7.7%)$13.53
FCF per share
CAGR: 2.2%FY+1$13.70
FY+2(-8.0%)$12.61
FY+3(+13.5%)$14.31
Historical Financials
Showing limited histrical data.
Income
RevenueOperating IncomeNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
Stock-based Comp.FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data
EPS (Basic)FCF/ShareDividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios
P/EP/SEV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
ROICROAROCEROE
Shares outstanding
Shares (Basic)Shares (Diluted)
Market Cap.
Market Cap.
KPIs
Revenue By Geography
Western Hemisphere Excluding USAsia Pacific and AfricaUSEurope
Revenue By Segment
MedtechPharmaceuticalConsumer Health
Similar Companies
Ownership
Major holders
Insiders: 0.06%
Institutions: 73.94%
Other: 26.00%
Institutions: 73.94%
Other: 26.00%
Institutional ownership
Insider transactions
Show:
Buys
Sells
Grants
| Date | Shares | Total ($) | Price ($) | Name | Title | |
| Sell | 2025-07-17 | 19,137 | 3,129,830 | 163.5 | REED JOHN C | Officer |
| Grant | 2025-03-18 | 130,852 | 0 | 0.0 | DUATO JOAQUIN BOIX | Chief Executive Officer |
| Grant | 2025-02-25 | 6,999 | 712,988 | 101.9 | DECKER ROBERT J | Officer |
| Sell | 2025-02-25 | 6,999 | 1,160,994 | 165.9 | DECKER ROBERT J | Officer |
| Sell | 2025-02-18 | 403 | 62,928 | 156.1 | SCHMID TIMOTHY | Officer |
| Grant | 2025-02-07 | 13,015 | 1,302,281 | 100.1 | WOLK JOSEPH J | Chief Financial Officer |
| Grant | 2025-02-07 | 58,504 | 5,853,910 | 100.1 | TAUBERT JENNIFER L | Officer |
| Grant | 2025-02-07 | 126,369 | 12,644,482 | 100.1 | DUATO JOAQUIN BOIX | Chief Executive Officer |
| Grant | 2025-02-07 | 32,762 | 3,278,166 | 100.1 | WENGEL KATHRYN E | Chief Operating Officer |
| Sell | 2025-02-07 | 13,015 | 2,002,878 | 153.9 | WOLK JOSEPH J | Chief Financial Officer |
| Buy | 2024-12-12 | 1,000 | 147,220 | 147.2 | WEINBERGER MARK A | Director |
| Grant | 2024-10-17 | 68,890 | 0 | 0.0 | WOLK JOSEPH J | Chief Financial Officer |
| Grant | 2024-08-30 | 5,635 | 563,838 | 100.1 | DECKER ROBERT J | Officer |
| Sell | 2024-08-30 | 5,635 | 930,113 | 165.1 | DECKER ROBERT J | Officer |
Tools
Dividend Income
| Investment Amount | |
| Dividend Yield |
What is the Dividend Income Calculator?
The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.
How to Use This Calculator?
Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.
Required Investment
| Dividend Yield | |
| Desired Yearly Payout | |
| Desired Quarterly Payout | |
| Desired Monthly Payout |
What is the Required Investment Calculator?
The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.
How to Use This Calculator?
Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.
Future Dividend Yield
| Base Dividend | |
| Current Price | |
| Number of Years | |
| Dividend Growth Rate |
What is the Future Yield Calculator?
The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.
How to Use This Calculator?
Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.
Future Dividend Income
| Base Dividend | |
| Number of Years | |
| Dividend Growth Rate |
What is the Future Dividend Income Calculator?
The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.
How to Use This Calculator?
Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.